Psilocybin End-of-Life Therapy: One Man's Fight for the Right to Die in Peace

One man's fight for psilocybin at the end of life — and why it matters for everyone, everywhere.

A Father, a Diagnosis, and a Door That Closed

Pete Pearson — known to everyone as "Pistol Pete" — lives in a small town along the St. Clair River in Ontario, Canada. Five years ago, he was diagnosed with idiopathic pulmonary fibrosis, a progressive and incurable lung disease. The average survival time is three to five years. Pete has already beaten that estimate, but each day brings him closer to an ending he cannot avoid.

As his breathing worsened, something else crept in. Not physical pain, but a deeper kind of suffering — the kind that sits between fear and grief. End-of-life distress. The constant awareness that time is running out, combined with helplessness, anxiety, and an aching sense of loss for the life still happening around you. Pete tried at least six different medications. He tried therapy. He tried meditation. Nothing worked.

Then Pete learned about psilocybin end-of-life therapy — the growing body of research showing that a single guided session with psilocybin can profoundly reduce anxiety and depression in people with terminal illness. Studies from NYU, Johns Hopkins, and Imperial College London have shown lasting improvements in outlook, acceptance, and quality of life. Pete wanted that chance.

Eleven Months, Fourteen Pages, and a No

Pete's son — himself a physician — submitted a formal application in October 2024 through his country's special access program. The request included medical records, clinical rationale, and supporting research. Then they waited. Eleven months passed. The answer finally arrived in July 2025: a fourteen-page rejection letter, explaining that Pete's situation did not qualify as an emergency and that "conventional alternatives" were available.

Pete had already tried those conventional alternatives. All of them. For years. His son described the rejection as "a slap in the face of science and compassion." What made it worse was that the same government readily offered Pete access to medically assisted death — a legal option for terminally ill patients in Canada. As Pete put it: "I fought for a year for something to help me live better, and they told me they could help me die faster."

This is not a uniquely Canadian problem. It is a pattern repeated in countries around the world. The science on psilocybin is moving faster than the laws. In most nations, psilocybin remains classified alongside the most dangerous drugs — Schedule I in the United States, Schedule 9 in Australia's old framework, and similarly restricted across much of Europe, Asia, Africa, and Latin America. Even in places where compassionate access pathways exist, bureaucratic gatekeeping blocks most patients who apply.

Psilocybin End-of-Life Therapy: What the Research Shows

The evidence for psilocybin end-of-life therapy is not speculative. It rests on multiple controlled clinical trials with remarkably consistent results.

These are not fringe experiments. This is peer-reviewed, institutional-grade science conducted at some of the most respected medical centers in the world. The question is no longer whether psilocybin helps dying people. The question is why governments continue to block access to it.

What Pete Did Next

On January 3, 2026, Pete made a decision. After exhausting every legal avenue, he sat on his couch at home, looked out over the frozen river, and drank a cup of psilocybin mushroom tea. It cost about forty dollars. The session lasted eight hours.

When it was over, Pete described a transformation he did not expect. "I cannot believe how dramatically my outlook on life has changed," he told CBC Radio in April 2026. The fear that had consumed him for years — the anxiety about dying, the grief about leaving his family — was gone. Not suppressed. Not dulled. Gone. Replaced by something he had not felt in a very long time: gratitude for the life he still has.

Pete's story became public through a CBC Radio documentary aired on April 7, 2026. It reached millions of people — and it struck a nerve. Not because Pete's case is unusual, but because it is achingly common. Across every continent, people facing terminal illness are denied the same chance Pete had to take for himself.

This Is Not About One Country — It Is About Human Dignity

Pete lives in Canada. But the same struggle is playing out everywhere. A cancer patient in Germany can technically apply for compassionate access to psilocybin, but the process is slow and uncertain. A dying person in the United Kingdom has no legal pathway at all. In most of Africa, Asia, and South America, psilocybin end-of-life therapy does not exist as a legal concept. Even in the United States, where Oregon and Colorado have created supervised psilocybin programs, federal law still classifies psilocybin as Schedule I — meaning "no accepted medical use."

Meanwhile, the legal status of psilocybin is shifting. The Czech Republic became the first EU country to allow medical psilocybin prescriptions from January 2026. Australia began its authorized prescriber program in 2023. But even in these pioneering countries, access remains limited. In Australia, fewer than 50 patients received psilocybin therapy in the first 18 months of the program.

At the heart of this issue is a simple question of human dignity. When a person is dying — when medicine has done everything it can for the body — should a government have the right to prevent that person from finding peace of mind? Pete Pearson does not think so. And increasingly, neither do the doctors, researchers, and advocates working to change the system.

Psilocybin End-of-Life Therapy: Where It Stands in 2026

Although progress is slow, doors are opening. Here is where legal access to psilocybin for terminal patients currently exists — and where it is being fought for:

Organizations Fighting for Access

Pete Pearson did not fight alone. Across the world, organizations are working to ensure that people facing death — and people dealing with serious mental health conditions — can legally access psilocybin end-of-life therapy and other psychedelic-assisted treatments. If this cause matters to you, these are the organizations that deserve your attention and support:

Patient Advocacy and Legal Access

Research and Education

Policy and Legal Reform

What You Can Do

You do not have to be a politician, a researcher, or a terminally ill patient to make a difference. The movement for psilocybin end-of-life therapy access grows through individual voices. Here are concrete steps anyone can take: